Identification of main human urinary metabolites of the designer nitrobenzodiazepines clonazolam, meclonazepam, and nifoxipam by nano-liquid chromatography-high-resolution mass spectrometry for drug testing purposes
- 806 Downloads
Among the new psychoactive substances (NPS), so-called designer benzodiazepines have become of particular importance over the last 2 years, due to their increasing availability on the internet drug market. Therapeutically used nitrobenzodiazepines such as flunitrazepam are known to be extensively metabolized via N-dealkylation to active metabolites and via nitro reduction to the 7-amino compounds. The aim of the present work was to tentatively identify phase I and II metabolites of the latest members of this class appearing on the NPS market, clonazolam, meclonazepam, and nifoxipam, in human urine samples. Nano-liquid chromatography-high-resolution mass spectrometry was used to provide data about their detectability in urine. Data revealed that clonazolam and meclonazepam were extensively metabolized and mainly excreted as their amino and acetamino metabolites. Nifoxipam was also extensively metabolized, but instead mainly excreted as the acetamino metabolite and a glucuronic acid conjugate of the parent. Based on analysis of human urine samples collected in cases of acute intoxication within the Swedish STRIDA project, and samples submitted for routine drug testing, the most abundant metabolites and good targets for urine drug testing were 7-aminoclonazolam for clonazolam, 7-acetaminomeclonazepam for meclonazepam, and 7-acetaminonifoxipam for nifoxipam.
KeywordsNew psychoactive substances NPS Metabolism Benzodiazepines Urine Mass spectrometry
The STRIDA project was supported by grants from the Public Health Agency of Sweden.
Compliance with ethical standards
The study was conducted in accordance with the Helsinki Declaration. The use of de-identified leftover volumes from the routine samples pool (No. 00-230) and the STRIDA project (No. 2013/116–31/2) were approved by the regional ethical review board.
Conflict of interest
The authors declare that they have no conflicts of interest.
- 1.UNODC. World Drug Report United Nations publication Sales No. E.14.XI.7. 2014.Google Scholar
- 2.EMCDDA. New psychoactive substances in Europe. EMCDDA Annual Report, 2015.Google Scholar
- 3.UNODC. World Drug Report United Nations publication Sales No. E.15.XI.6, 2015.Google Scholar
- 29.Valaskovic GA, Utley L, Lee MS, Wu JT. Ultra-low flow nanospray for the normalization of conventional liquid chromatography/mass spectrometry through equimolar response: standard-free quantitative estimation of metabolite levels in drug discovery. Rapid Commun Mass Spectrom. 2006;20(7):1087–96.CrossRefGoogle Scholar
- 37.Smyth WF, Joyce C, Ramachandran VN, O’ Kane E, Coulter D. Characterisation of selected hypnotic drugs and their metabolites using electrospray ionisation with ion trap mass spectrometry and with quadrupole time-of-flight mass spectrometry and their determination by liquid chromatography-electrospray ionisation-ion trap mass spectrometry. Anal Chim Acta. 2004;506(2):203–14.CrossRefGoogle Scholar
- 38.Bourcier K, Hyland R, Kempshall S, Jones R, Maximilien J, Irvine N, et al. Investigation into UDP-glucuronosyltransferase (UGT) enzyme kinetics of imidazole- and triazole-containing antifungal drugs in human liver microsomes and recombinant UGT enzymes. Drug Metab Dispos. 2010;38(6):923–9.CrossRefGoogle Scholar
- 39.Court MH, Hao Q, Krishnaswamy S, Bekaii-Saab T, Al-Rohaimi A, von Moltke LL, et al. UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver. J Pharmacol Exp Ther. 2004;310(2):656–65.CrossRefGoogle Scholar